Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery

European Heart Journal

Volumn 30, Issue 8, 2009, Pages 995-1004

  Ranucci, Marco ^a   Ballotta, Andrea ^a   Frigiola, Alessandro ^a   Boncilli, Alessandra ^a   Brozzi, Simonetta ^a   Costa, Elena ^a   Mehta, Rajendra H ^b  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac surgery; Homocysteine; Outcomes; Risk factors

Indexed keywords

HOMOCYSTEINE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL FEATURE; FEMALE; HEART OUTPUT; HEART SURGERY; HUMAN; HYPERHOMOCYSTEINEMIA; INFARCTION; MAJOR CLINICAL STUDY; MALE; MESENTERY INFARCTION; MORBIDITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL MORTALITY; THROMBOEMBOLISM;

AGED; CARDIOPULMONARY BYPASS; EPIDEMIOLOGIC METHODS; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INTRAOPERATIVE COMPLICATIONS; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; THROMBOEMBOLISM; YOUNG ADULT;

EID: 65249151329     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp015     Document Type: Article

References (30)

1. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015- 2022.
2. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-375.
3. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
4. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocys-t(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002;31:59-70.
5. Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997;157:2299-2308.
6. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398.
7. Stubbs PJ, Al-Obaidi MK, Conroy RM, Collinson PO, Graham IM, Noble MIM. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000;102:605-610.
8. Bostom AG, Silbershatz H, Rosenberg IH, Jacques PF, Selhub J, D'Agostino RB, Wilson PW, Wolf PA. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077-1080.
9. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005;3:1646-1654.
10. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-318.
11. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J Nutr 1996;126:1285S- 1289S.
12. The PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery-PREVENT IV: a randomized controlled trial. JAMA 2005; 294:2446-2454.
13. Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg 1994;57: 12-19.
14. Desai ND, Cohen EA, Naylor CD, Fremes SE, for the Radial Artery Patency investigators. N Engl J Med 2004;351:2302-2309.
15. Anyanwu AC, Filsoufi F, Salzberg SP, Bronster DJ, Adams DH. Epidemiology of stroke after cardiac surgery in the current era. J Thorac Cardiovasc Surg 2007; 134:1121-1127.
16. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:816-822.
17. Brunelli T, Pepe G, Marcucci R, Giusti B, Prisco D, Abbate R, Fedi S. Comparison of three methods for total homocysteine plasma determination. Clin Lab 2001;47: 393-397.
18. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocys-teine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577.
19. de Bree A, van der Put NM, Mennen LI, Verschuren WM, Blom HJ, Galan P, Bates CJ, Herrmann W, Ullrich M, Dierkes J, Westphal S, Bouter LM, Heine RJ, Stehouwer CD, Dekker JM, Nijpels GN, Araújo F, Cunha-Ribeiro LM, Refsum H, Vollset S, Nygard O, Ueland PM. Prevalences of hyperhomocysteinemia, unfavorable cholesterol profile and hypertension in European populations. Eur J Clin Nutr 2005;59:480-488.
20. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer H. The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am J Hum Genet 1985;37:1-31.
21. Schimke RN, McKusick VA, Huang T, Pollack AD. Homocystinuria: studies of 20 families with 38 affected members. JAMA 1965;193:711-719.
22. Storti S, Cerrillo AG, Rizza A, Giannelli I, Fontani G, Glauber M, Clerico A. Coronary artery bypass grafting surgery is associated with a marked reduction in serum homocysteine and folate levels in the early postoperative period. Eur J Car-diothorac Surg 2004;26:682-686.
23. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993;92:1381-1386.
24. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
25. Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005;33: 355-360.
26. Ranucci M, Ditta A, Boncilli A, Cotza M, Carboni G, Brozzi S, Bonifazi C, Tiezzi A. Determinants of antithrombin consumption in cardiac operations requiring cardi-opulmonary bypass. Perfusion 2004;19:47-52.
27. Boyle EM Jr, Morgan EN, Verrier ED. The endothelium disturbed: the procoagu-lant response. In Spiess BD, ed., The Relationship Between Coagulation, Inflammation and Endothelium - a Pyramid Towards Outcome. Baltimore, MD: Lippincot Williams and Wilkins; 2000. p79-89.
28. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-812.
29. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, NORVIT Trial Investigators. Homocys-teine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
30. Koster A, Chew D, Kuebler W, Habazettl H, Hetzer R, Kuppe H. High antithrombin III levels attenuate hemostatic activation and leukocyte activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003;126: 906-907.